Comparison of One- and 12-Month Outcomes of TAVR in Patients With Severely Stenotic Bicuspid Versus Tricuspid Aortic Valves (Results from a Multicenter Registry)

Bicuspid aortic valve (BAV) stenosis has been regarded as a relative contraindication for transcatheter aortic valve implantation (TAVI). In this retrospective study of patients from 5 different centres undergoing TAVI for severe aortic stenosis, the authors compare outcomes between a group of 28 patients with BAV and a 1:3 matched group of 84 patients with tricuspid aortic valves (TAV). Uneven expansion of the bioprosthesis was commonly observed in the BAV group. However, this did not influence the overall procedural outcomes. There were no significant differences in 30-day mortality, one-year all-cause mortality, 30-day combined safety end points, and more than mild aortic regurgitation between the two groups. Based on this data, the authors suggest that selected patients with stenotic BAV, can be successfully treated with TAVI.